- Home
- JFBR vs LITS Comparison
JFBR vs LITS Comparison
Compare JFBR & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JFBR | LITS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Israel | United States |
| Employees | 11 | 4 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 40.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JFBR | LITS |
|---|---|---|
| Price | $3.72 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.8K | ★ 292.3K |
| Earning Date | 03-31-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.95 |
| 52 Week High | $7.87 | $3.03 |
Technical Indicators
Market Signals| Indicator | JFBR | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 52.44 |
| Support Level | $3.58 | $1.17 |
| Resistance Level | $5.40 | $1.27 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 6.06 | 61.11 |
Price Performance
Historical ComparisonAbout JFBR Jeffs' Brands Ltd
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.